# A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

> **NCT07385001** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Ivonescimab
- Neoadjuvant

## Interventions

- **DRUG:** AK112
- **DRUG:** AK112
- **DRUG:** AK112 + Neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT07385001
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2027-01-28
- **Final completion:** 2028-01-28
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07385001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07385001, "A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT07385001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*